| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
1-(aD-ribofuranosyl)uracil targets cellular processes involved in nucleic acid synthesis. As a purine nucleoside analog, it has broad antitumor activity targeting indolent lymphoid malignancies. The compound's mechanism involves incorporation into nucleic acids, leading to disruption of DNA and RNA synthesis. It has been investigated for biological activities in cancer treatment and antiviral applications.
|
|---|---|
| ln Vitro |
1-(aD-ribofuranosyl)uracil demonstrates in vitro activity as a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. The compound's activity is typically assessed in cellular assays measuring cell proliferation, viability, and apoptosis in cancer cell lines. It has garnered attention for its biological activities in cancer treatment and antiviral applications.
|
| ln Vivo |
In vivo studies for 1-(aD-ribofuranosyl)uracil have not been extensively documented in the available literature. As a purine nucleoside analog, it has potential for in vivo applications in cancer therapy and antiviral treatment. Studies in appropriate animal models would be needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile. The compound has garnered attention for its biological activities.
|
| Enzyme Assay |
For cellular activity assays, 1-(aD-ribofuranosyl)uracil is tested against cancer cell lines at various concentrations. Cell viability is assessed using MTT or CellTiter-Glo assays, and IC50 values are calculated from dose-response curves. Apoptosis induction is assessed by caspase-3/7 activity or Annexin V staining. DNA and RNA synthesis inhibition is measured by incorporation of radiolabeled precursors.
|
| Cell Assay |
For cellular studies, appropriate cancer cell lines are cultured in appropriate media and treated with 1-(aD-ribofuranosyl)uracil at various concentrations. Cells are incubated for 24-72 hours, and cell viability is assessed using MTT or CellTiter-Glo assays. Cell cycle analysis is performed using propidium iodide staining and flow cytometry. Apoptosis induction is assessed by caspase-3/7 activity or Annexin V staining. DNA and RNA synthesis is measured by incorporation of radiolabeled precursors.
|
| Animal Protocol |
For in vivo efficacy studies, appropriate animal models of cancer would be used. 1-(aD-ribofuranosyl)uracil would be administered via appropriate routes at various doses. Tumor volume would be measured, and body weight monitored for toxicity. Pharmacokinetic parameters including half-life, clearance, and tissue distribution would be determined. However, detailed in vivo protocols for 1-(aD-ribofuranosyl)uracil have not been extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 1-(aD-ribofuranosyl)uracil have not been fully characterized in the available literature. The compound has a molecular formula of C9H12N2O6 and a molecular weight of 244.20. Purity is ≥95%. It is a purine nucleoside analog. Comprehensive PK studies including bioavailability, half-life, protein binding, and tissue distribution are needed to fully understand its ADME properties.
|
| Toxicity/Toxicokinetics |
1-(aD-ribofuranosyl)uracil is a research compound intended for laboratory use only and is not approved for human therapeutic use. As a purine nucleoside analog, it has broad antitumor activity targeting indolent lymphoid malignancies. Standard laboratory safety precautions should be followed when handling this compound. Purity ≥95%.
|
| References | |
| Additional Infomation |
1-(aD-ribofuranosyl)uracil is a purine nucleoside analog with molecular formula C9H12N2O6 and molecular weight 244.20. It has garnered attention for its biological activities in cancer treatment and antiviral applications. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. It is for research use only and has not been approved for clinical applications. Purity ≥95%.
|
| Molecular Formula |
C9H12N2O6
|
|---|---|
| Molecular Weight |
244.20
|
| Exact Mass |
244.07
|
| CAS # |
3258-07-9
|
| PubChem CID |
1521749
|
| Appearance |
White to off-white solid powder
|
| LogP |
-2
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
371
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CN(C(=O)NC1=O)[C@@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
|
| InChi Key |
DRTQHJPVMGBUCF-JBBNEOJLSA-N
|
| InChi Code |
InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7-,8+/m1/s1
|
| Chemical Name |
1-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (409.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0950 mL | 20.4750 mL | 40.9500 mL | |
| 5 mM | 0.8190 mL | 4.0950 mL | 8.1900 mL | |
| 10 mM | 0.4095 mL | 2.0475 mL | 4.0950 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
